These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 12908369

  • 21. Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications.
    Vogelvang TE, van der Mooren MJ, Mijatovic V.
    Treat Endocrinol; 2004; 3(2):105-15. PubMed ID: 15743106
    [Abstract] [Full Text] [Related]

  • 22. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system?
    Rosano GM, Vitale C, Fini M.
    Ann N Y Acad Sci; 2006 Dec; 1092():341-8. PubMed ID: 17308159
    [Abstract] [Full Text] [Related]

  • 23. Role of estrogens, selective estrogen receptor modulators and phytoestrogens in cardiovascular protection.
    Herrington D.
    Can J Cardiol; 2000 Aug; 16 Suppl E():5E-9E. PubMed ID: 10906617
    [Abstract] [Full Text] [Related]

  • 24. [SERM for early osteoporosis therapy. Risk for first spinal fracture reduced to half].
    MMW Fortschr Med; 2003 May 29; 145(22):57. PubMed ID: 12866287
    [No Abstract] [Full Text] [Related]

  • 25. Differential effects of alternatives to hormone replacement therapy in postmenopausal healthy women.
    Bjarnason NH.
    Dan Med Bull; 2005 May 29; 52(2):64-81. PubMed ID: 16009050
    [No Abstract] [Full Text] [Related]

  • 26. Prevention of cardiovascular events in early menopause: a possible role for hormone replacement therapy.
    Antonicelli R, Olivieri F, Morichi V, Urbani E, Mais V.
    Int J Cardiol; 2008 Nov 12; 130(2):140-6. PubMed ID: 18617278
    [Abstract] [Full Text] [Related]

  • 27. Postmenopausal hormone therapy and the risk of cardiovascular disease.
    Stramba-Badiale M.
    J Cardiovasc Med (Hagerstown); 2009 Apr 12; 10(4):303-9. PubMed ID: 19430340
    [Abstract] [Full Text] [Related]

  • 28. Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.
    Dias AR, Melo RN, Gebara OC, D'Amico EA, Nussbacher A, Halbe HW, Pinotti JA.
    Climacteric; 2005 Mar 12; 8(1):63-70. PubMed ID: 15804733
    [Abstract] [Full Text] [Related]

  • 29. The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women.
    Alexandersen P, Tankó LB, Bagger YZ, Qin G, Christiansen C.
    Climacteric; 2006 Apr 12; 9(2):108-18. PubMed ID: 16698657
    [Abstract] [Full Text] [Related]

  • 30. The cardiovascular effects of selective estrogen receptor modulators.
    Christodoulakos GE, Lambrinoudaki IV, Botsis DC.
    Ann N Y Acad Sci; 2006 Dec 12; 1092():374-84. PubMed ID: 17308162
    [Abstract] [Full Text] [Related]

  • 31. [Additional effect of SERM: central nervous system].
    Honjo H.
    Clin Calcium; 2004 Oct 12; 14(10):69-72. PubMed ID: 15577134
    [Abstract] [Full Text] [Related]

  • 32. Cardiovascular effects of estrogen replacement therapy.
    Chae CU, Manson JE.
    Adv Intern Med; 2001 Oct 12; 47():47-88. PubMed ID: 11795080
    [No Abstract] [Full Text] [Related]

  • 33. [Historical perspective of hormone replacement therapy].
    Chanson P.
    Rev Prat; 2005 Feb 28; 55(4):369-75. PubMed ID: 15828614
    [Abstract] [Full Text] [Related]

  • 34. Prevention of hormone-related cancers: breast cancer.
    Dunn BK, Wickerham DL, Ford LG.
    J Clin Oncol; 2005 Jan 10; 23(2):357-67. PubMed ID: 15637398
    [Abstract] [Full Text] [Related]

  • 35. Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women.
    da Costa LS, de Oliveira MA, Rubim VS, Wajngarten M, Aldrighi JM, Rosano GM, Neto CD, Gebara OC.
    Am J Cardiol; 2004 Dec 01; 94(11):1453-6. PubMed ID: 15566926
    [Abstract] [Full Text] [Related]

  • 36. Raloxifene: another selective estrogen modulator.
    Kellen JA.
    In Vivo; 2001 Dec 01; 15(6):459-60. PubMed ID: 11887329
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Estrogens and selective estrogen receptor modulators in the treatment of osteoporosis].
    Ribot C, Tremollieres F, Pouilles JM.
    Ann Med Interne (Paris); 2000 Oct 01; 151(6):490-6. PubMed ID: 11104929
    [Abstract] [Full Text] [Related]

  • 39. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL, Chao HT, Cheng MH, Wang PH.
    Maturitas; 2008 Jun 20; 60(2):92-107. PubMed ID: 18534794
    [Abstract] [Full Text] [Related]

  • 40. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
    Aldrighi JM, Quail DC, Levy-Frebault J, Aguas F, Kosian K, Garrido L, Bosio-Le Goux B, Saráchaga M, Graebe A, Niño AJ, Nickelsen T.
    Am J Obstet Gynecol; 2004 Dec 20; 191(6):1979-88. PubMed ID: 15592280
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.